← All trials
NCT06974851
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 25, 2025
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2026
- First posted
- May 16, 2025
- Last posted
- Nov 17, 2025
- Enrollment
- 140
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Jiangsu ShengDiYa Medicine Co., Ltd.Lead sponsor
Drugs studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.